Qt Imaging Holdings, Inc. · NASDAQ:QTI
Qt Imaging — Q2 2026 Earnings Presentation
32 slides from Qt Imaging's earnings presentation, Aug 12, 2026
Slide 1: Quantitative Transmission Imaging
NASDAQ:QTI Quantitative Transmission Imaging Breast Acoustic CT Scanner August 2026 Copyright ©2026 QT Imaging, Inc. All Rights Reserved.
Slide 2: Disclaimer
Disclaimer ABOUT THIS PRESENTATION This investor presentation (this “Presentation”) is provided for informational purposes only. The information contained herein does not purport to be all-inclusive and neither QT Imaging Holdings, Inc. (the “Company”, “QT Imaging Holdings”, “QTI”), nor its respecti
Slide 3: Disclaimer: Forward Looking Statements
Disclaimer FORWARD LOOKING STATEMENTS Certain statements included in this Presentation that are not historical facts are forward -looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements general
Slide 4: Our Mission: Transforming Breast Health For Every Woman
Our Mission Transforming Breast Health For Every Woman At QT Imaging, we are redefining what’s possible in breast imaging - delivering safe, high-resolution, and cost-effective solutions where traditional technologies fall short. Our goal is to replace outdated breast imaging workflows with the firs
Slide 5: QT Imaging Transformation
QT Imaging Transformation $18M from NIH to develop QTI becomes Approval of Regulatory approvals supplemental imaging modality public on Reimbursement in Saudi Arabia, to resolve dense breasts NASDAQ Category III CPT Code UAE and Israel 2012-2025 Mar 2024 Feb 2026 Mar - Jun 2026 2012 2017 Oct 2025 Ma
Slide 6: The Pain and Why QT Imaging
The Pain and Why QT Imaging The Pain Why QT Imaging • Mammography misses cancers in dense • QT Imaging has uniquely breasts / it is painful differentiated solution • MRI is expensive / slow / uncomfortable / • Accurate diagnosis in dense breasts contrast injection • No compression, no radiation expo
Slide 7: Accurate Imaging for Dense Breasts
Accurate Imaging for Dense Breasts Today’s Challenge: QT Imaging Solution: Multi-step, patient anxiety and attrition Single step (Supplemental + Dx) patient prone process with high number of friendly process, with potential to reduce unnecessary biopsies unnecessary biopsies Primary Breast Density S
Slide 8: QT Imaging Value Proposition
QT Imaging Value Proposition For the Patient For the Clinician For the Administrator • One-stop-shop supplemental • One test – multiple results • 2.5 X more revenue per scan + diagnostic imaging (MRI like Imaging) compared to mammography + handheld ultrasound • Calcium visualization (DCIS + Ca, • No
Slide 9: Our Technology and Product
Our Technology and Product • FDA-cleared, patent protected breast imaging modality • Pain free, safe, no radiation or contrast • Inherently 3D quantitative, imaging modality, thus it’s high resolution, similar to MRI • Two independent sources of information: − CT-like configuration with ultrasound t
Slide 10: Optimized Patient Experience
Optimized Patient Experience • No ionizing radiation. Acoustic source only • No breast compression and associated discomfort • 10-12 minutes per breast exam time • Quiet and comfortable (compared to MRI – claustrophobia, coil pressure, noise, lengthy exams) • No contrast injection or associated risk
Slide 11: Our Market, Why Now, and How It Fits In
Our Market, Why Now, and How It Fits In
Slide 12: QT Imaging's Technology Has the Opportunity to Transform the Breast Imaging Market
QT Imaging’s Technology Has the Opportunity to Transform the Breast Imaging Market CURRENT MARKET NEW MARKET 2026 2030 Breast Imaging: Layer Description CAGR SaaS Biomarkers: Value Value $6B MARKET (1) $1B MARKET (3) • FDA approved as supplemental Total global opportunity • Move to personalized, scr
Slide 13: Three Tailwinds Positioning QT Imaging for Growth
Three Tailwinds Positioning QT Imaging for Growth Regulatory Tailwinds AI Tailwinds Oncology Tailwinds The FDA Has Recognized the Radiology is the leading Oncology is moving from one- Importance of Breast Density specialty for clinical size-fits-all treatment toward in Breast Cancer Screening AI ado
Slide 14: Breast Cancer Screening Matrix: QT Imaging Sweet Spot
Breast Cancer Screening Matrix: QT Imaging Sweet Spot Risk Category (Tyrer-Cuzick Lifetime Risk) Typical Risk Profile Description < 40 Years ≥ 40 Years + Breast Density No first-degree relatives with breast cancer No known pathogenic mutations Mammography Low Risk (<12%) No routine imaging; No prior
Slide 15: Validation
gy QT IMAGING Validation
Slide 16: Clinical Advisory Board
Clinical Advisory Board Dr. Mary Yamashita, MD Dr. Barry Roseman, MD, FACS Dr. John Tentinger Section Chief of Breast Imaging at A fellowship-trained surgical A Mayo Clinic-trained, board- USC's Keck School of Medicine and oncologist and breast surgeon certified radiologist and founder of a longtime
Slide 17: Growing Global Validation
Growing Global Validation • Existing FDA clearance to offer an imaging modality for all patients above 18 years old NIH has awarded QT • Received Saudi Arabia, UAE, and Israel regulatory Imaging about approvals $18M • NIH $18M funding to generate a safe imaging for new women’s modality for women wit
Slide 18: Mayo Clinic – QT Scan vs MRI
Clinical Validation Across Screening & Oncology Applications: Mayo Clinic – QT Scan vs MRI QT Scan • Mayo Clinic prospective feasibility study: 26 high-risk women comparing QT Imaging (QT Scan) with breast MRI for supplemental screening • Strong breast-level agreement with MRI: binary agreement betw
Slide 19: Sunnybrook Cancer Center – QT Scan vs MRI
Clinical Validation Across Screening & Oncology Applications: Sunnybrook Cancer Center – QT Scan vs MRI • NIH/NCI-funded, to prove QT Imaging as imaging QT Scan modality for early monitoring of breast cancer response to neoadjuvant chemotherapy (NAC) • Major oncology need: − treatment response that
Slide 20: Multi-site Repeatability & Reproducibility Study
Multi-site Repeatability & Reproducibility Study • Multi-site study (2 sites, 5 patients/site, 5 scans each) confirms QT Imaging's quantitative biomarkers are highly reproducible within and across scanners • Speed of Sound (SoS), our core tissue biomarker, showed less than 1% variability, a level of
Slide 21: Expanded Global Regulatory Foundation
Expanded Global Regulatory Foundation Saudi FDA (SFDA) Submitted Dossier Feb, 2026 Under SFDA Approved Authorized Rep via Gulf Medical; Regulatory Review June 2026 MDS-GS-004 UAE (MOHAP) Dossier Preparation UAE Submission Approved Leverage SFDA submission; MOHAP device March 2026 MOHAP registration
Slide 22: Business Model, Partnerships & Financial Trajectory
Business Model, Partnerships & Financial Trajectory
Slide 23: Business Model
Business Model HW+ SaaS +AI Diagnostic Layer Cloud SaaS Platform Business Model: • Hardware sale (scanner): upfront revenue • SaaS platform: Radiology Referring MD recurring revenue • AI diagnostic layer: higher margin Hardware gets us in the door. Software builds the company. Copyright ©2026 QT Ima
Slide 24: Planned Evolution to Hybrid Commercial Model as Scale Increases
Planned Evolution to Hybrid Commercial Model as Scale Increases 2024-2026 2027 and beyond Distributor Led Hybrid Model • Broad market coverage • Direct leads strategic accounts • Capital efficient • Distributor supports service and • Rapid deployment financing Hospitals / IDNs Outpatient Imaging Cha
Slide 25: Business Partnerships Today
Business Partnerships Today Under Distribution Under Distribution Under Distribution Under Distribution Agreement with Agreement with Gulf Agreement with Al Agreement with Re- NXC Imaging Medical for Kingdom Naghi Medical for the Invent Pharma for the (Subsidiary of Canon of Saudi Arabia (KSA) Unite
Slide 26: QTI Precision Pathway – Cloud SaaS Platform
QTI Precision Pathway – Cloud SaaS Platform Core Operational Advanced Enterprise System software Collaboration & Quantitated Multiuser access updates data sharing biomarkers Enterprise Long term technology Automated analysis collaboration relevance Precision reporting Biomarker / Analysis QTI Precis
Slide 27: Financial Trajectory
Financial Trajectory Yearly Revenue and Scanner Shipments Quarterly Revenue and Scanner Shipments $45.0 90 $9.00 17 18 $39.0 $40.0 80 $8.00 15 16 $7.00 13 14 $35.0 70 $30.0 60 $6.00 12 Shipments (#) Revenue ($M) Shipments (#) Revenue ($M) $5.00 9 10 $25.0 50 8 $18.9 $20.0 40 $4.00 8 6 $15.0 30 $3.00
Slide 28: Financial Trajectory
Financial Trajectory Revenue/scanner, Gross Margin, and Unit Economics (Adjusted EBITDA/Scanner) $600 100% $473 $488 $500 $407 80% $400 54% 60% $300 45% 45% $200 40% $100 20% $8 $- 0% $(100) $(88) -20% $(200) $(300) -40% $(400) -60% $(500) -80% $(600) $(700) $(613) -100% FY 2024 A FY 2025 A FY 2026
Slide 29: Manufacturing Capacity, Quality, and Compliance
Manufacturing Capacity, Quality, and Compliance • Expanded manufacturing capacity while improving operating efficiency − 22,000-square-foot headquarters and manufacturing facility − The expanded facility provides more than 2.5x the operational space of the current location while reducing lease cost
Slide 30: Building a Multi-Generational Voice for Breast Health Awareness
Building a Multi-Generational Voice for Breast Health Awareness Multi-Generational Reach Advocacy in Action • QTI is engaging with The Shift, a media platform • Presented the inaugural Shiftmaker Award reaching women across generations to tennis legend and cancer survivor Martina Navratilova • At Wi
Slide 31: QT Imaging Is Executing on Its Early Commercial Scale With Multiple Near Term Value Inflection Points
QT Imaging Is Executing on Its Early Commercial Scale With Multiple Near Term Value Inflection Points • FDA-cleared and commercially validated technology, established regulatory foundation with growing clinical adoption • Commercial infrastructure in place through manufacturing, distribution, and in
Slide 32: Thank You!
gy QT IMAGING Thank You!